Complex Generic Mid-Cycle Meetings: US FDA Suggests Taking The Date Offered

 
• By Derrick Gingery
Woman uses an inhaler during an asthma attack, close-up
The US FDA does not want complex generic sponsors to delay mid-cycle meetings if possible, because it could render them less productive.

More from Generics

More from Biosimilars & Generics